ISA Pharmaceuticals BV of the Netherlands has secured €8 million in funding from the Aglaia Oncology Fund and private investors to finance a Phase 2 study of its lead therapeutic vaccine candidate in cervical cancer. This a follow-on to an earlier Series A round.
